Spinal Cord Stimulator Market Forecast
Global Spinal Cord Stimulator Market held a value of USD 1,994.16 Million in 2018 and is expected to register a growth of 8.95% between 2019 and 2025.
Spinal Cord Stimulator Market Synopsis
Spinal cord stimulator (SCS) is a type of implantable neuromodulation device. The device is used to send electric signals to the pain areas of the spinal cord for the treatment of certain pain conditions. SCS is also known as a dorsal column stimulator (DCS) or a pain pacemaker. Increasing demand for minimally invasive procedures, a rise in the number of patients suffering from failed back surgery syndrome, a growing number of patients suffering from chronic & neuropathic pain and rising prevalence of degenerative disc disease (DDD) are the factors that are expected to drive the market growth. As per recent studies, spinal cord stimulation can be used to treat a variety of diseases that result in chronic pain. Treated diagnoses include complex regional pain syndrome type I (45%) and type II (4%), failed back surgery syndrome (FBSS) (33%), visceral pain (5%), neuropathy (10%), and peripheral vascular disease (3%).
As of May 2018, one-third of the global population aged 40 to 59 years have reported moderate to severe degenerative disc disease. Moreover, the growing R&D expenditure by companies to develop innovative spinal cord stimulators and increasing technological advancements are also expected to boost the market growth.
Spinal Cord Stimulator Market Influencer
Currently, there are very few medical device companies in the market that are into the manufacturing of spinal cord stimulator devices. This is expected to create lucrative opportunities for other players in the industry to enter the spinal cord stimulator market.
Spinal Cord Stimulator Market Drivers
- Increasing demand for minimally invasive procedures - Minimally invasive surgery became the most common method of repairing different types of heart and spine in developed countries. As per MRFR analysis, over 50% of spine surgery surgeries are performed using minimally invasive techniques.
- Rise in the number of patients suffering from failed back surgery syndrome – As of September 2018, 40% of the patients that suffer from chronic lower back pain have experienced continued pain after the surgery, which is also referred to as failed back surgery syndrome (FBSS).
- Increasing number of patients suffering from chronic & neuropathic pain
- Rising prevalence of degenerative disc disease
- Increasing R&D expenditure by companies to develop innovative spinal cord stimulator
- Rising technological advancements
Spinal Cord Stimulator Market Market Restraints
- Stringent government regulations related to product approvals.
- Major dependence on traditional therapies for the treatment
- Lack of awareness regarding the use of spinal cord stimulators for the treatment of neuropathic pain
- The dearth of skilled professionals. For instance, World Health Organization (WHO) estimates that based on a threshold of 4.4 skilled health professionals per 1000 population, the needs-based shortage of health-care workers globally would be about 17.4 million, of which almost 2.6 million are doctors, and over 9 million are nurses and midwives.
Spinal Cord Stimulator Market Segmentation
By Technology Type
- Conventional Implantable Pulse Generator (IPG): This segment held the largest market share in 2018 due to its cost-effectiveness and high usage by the hospitals.
- Rechargeable Implantable Pulse Generator: This segment is expected to be the fastest-growing during the forecast period owing to the stable product launches of rechargeable IPGs by companies. For instance, Boston Scientific Corporation launched the Spectra Wavewriter SCS system in January 2019 in Europe.
- Radiofrequency Stimulator: This type of stimulator also uses rechargeable batteries and is used in patients who suffer from pain in the lower legs and lower back as this device has low power.
- Failed Back Surgery Syndrome (FBSS): The segment held the largest market share in 2018 owing to the increasing prevalence of failed back surgery syndrome. In 2017, the prevalence of FBSS was 20.6%. Moreover, FBSS affects approximately 10% to 40% of patients who undergo back surgery.
- Complex Regional Pain Syndrome (CRPS): CRPS generally develops after an injury, surgery, stroke, or heart attack. The condition is also known as RSD or reflex sympathetic dystrophy syndrome. As per studies, the overall incidence rate of complex regional pain syndrome was 26.2 per 100,000 person-years with females affected at least three times more often than males. The highest incidence occurred in females aged 61-70 years (June 2018)
- Arachnoiditis: Arachnoiditis is a rare disorder that is caused by the inflammation of the arachnoid, which is a membrane that surrounds and protects the nerves of the spinal cord.
- Sciatica: Sciatica or Sciatic neuritis is a type of chronic pain that radiates from the lower back and goes through the hips & buttocks and the legs. The conditions generally affect only one side of the body.
- Degenerative Disc Disease (DDD): The segment is expected to grow at the fastest CAGR owing to the rising prevalence of the disease. DDD affects 85% of Americans by the age of 50.
- Others: Other conditions include angina, peripheral vascular disease, multiple sclerosis, spinal cord injury, and stump pain, among others.
- Hospitals and Clinics: This segment held the largest market share in 2018. Hospitals and clinics are the primary point of care for treatment, which is expected to drive the market growth.
- Ambulatory Surgical Centers: This segment is anticipated to register the fastest CAGR owing to the rising popularity of ambulatory surgical centers for carrying out surgeries in which the patient does not have to stay in the hospital for a longer period.
- Others: This includes research and academic institutes, and specialty clinics, among others.
- Americas: The largest regional market, owing to the rising prevalence of failed back surgery syndrome and the presence of major players in the market. As of April 2018, in the US, the overall failure rate of lumbar spine surgery was approximately 10% to 46%. Due to this, the number of patients suffering from FBSS is expected to increase continually.
- Europe: The spinal cord stimulator market in Europe held the second-largest position in 2018 owing to the rising prevalence of neuropathic pain and well-developed infrastructure in the region. As of December 2017, the prevalence of neuropathic pain in the European population was 7%. while 4% of responders had chronic pain secondary to nerve disease and 10% were being treated by neurologists/neurosurgeons
- Asia-Pacific: The fastest-growing regional market. The growth of the spinal cord stimulator market in this region is owing to the rapidly growing incidence rate of complex regional pain syndrome and the rising adoption of technologically advanced treatment options by the healthcare providers. As of 2019, the incidence rate of CRPS in South Korea was 29.0 per 100,000 persons.
- Middle East & Africa: The market is expected to hold the least market share owing to the poor healthcare infrastructure in the region.
Spinal Cord Stimulator Market Key Players
- Boston Scientific Corporation (US)
- Abbott (US)
- Nevro Corp. (US)
- Medtronic (Ireland)
- Stimwave LLC (US)
- Nuvectra (US)
- Beijing PINS Medical Co., Ltd (China)
- Cirtec (US)
- Synapse Biomedical Inc. (US)
- NeuroSigma, Inc. (US)
USD 1,994.16 Million
Value (USD Million)
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Technology Type, Application and End-User
North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Boston Scientific Corporation (US), Abbott (US), Nevro Corp. (US), Medtronic (Ireland), Stimwave LLC (US), Nuvectra (US), Beijing PINS Medical Co., Ltd (China), Cirtec (US), NeuroSigma, Inc. (US) and Synapse Biomedical Inc. (US)
Key Market Opportunities
There are very few medical device companies in the market that are into the manufacturing of spinal cord stimulator devices
Key Market Drivers
Increasing number of patients suffering from chronic & neuropathic painRising prevalence of degenerative disc diseaseIncreasing R&D expenditure by companies to develop innovative spinal cord stimulator
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.